Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 1, 2007, Pages 100-106

  Nguyen, T Hang ^a   Hoppe Tichy, T ^a   Geiss, H K ^a   Rastall, A C ^a   Swoboda, S ^a   Schmidt, J ^a   Weigand, M A ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Drug monitoring; Fungal; Mycology

Indexed keywords

ALBUMIN; CASPOFUNGIN; HYPERTENSIVE FACTOR; METHYLPREDNISOLONE; TACROLIMUS;

ADULT; AGED; ARTICLE; ASPERGILLUS FUMIGATUS; BLOOD SAMPLING; BODY WEIGHT; CANDIDA ALBICANS; CANDIDA GLABRATA; CLINICAL ARTICLE; CRITICAL ILLNESS; DRUG BLOOD LEVEL; FEMALE; FUNGUS ISOLATION; HUMAN; INTENSIVE CARE UNIT; LOADING DRUG DOSE; MALE; MYCOSIS; NONHUMAN; OPEN STUDY; PREDICTION; PROGNOSIS; STATISTICAL MODEL; SURGICAL PATIENT;

ADULT; AGED; ANTIFUNGAL AGENTS; ASPERGILLOSIS; BODY WEIGHT; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDIASIS; CRITICAL ILLNESS; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PEPTIDES, CYCLIC; PROGNOSIS; SERUM ALBUMIN; SURGICAL PROCEDURES, OPERATIVE;

EID: 34447555825     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm125     Document Type: Article

References (47)

1. Mohr JF, Wanger A, Rex JH. Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patients. Diagn Microbiol Infect Dis 2004; 48: 125-30.
2. Cook AM. Pharmacokinetic alterations of antimicrobials in the critically ill. J Pharm Pract 2005; 18: 75-83.
3. Bodenham A, Shelly MP, Park GR. The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients. Clin Pharmacokinet 1988; 14: 347-73.
4. Townsend PL, Fink MP, Stein KL et al. Aminoglycoside pharmacokinetics: Dosage requirements and nephrotoxicity in trauma patients. Crit Care Med 1989; 17: 154-7.
5. De Paepe P, Belpaire FM, Buylaert WA. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet 2002; 41: 1135-51.
6. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: A review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005; 44: 1009-34.
7. Dive A, Foret F, Jamart J et al. Effect of dopamine on gastrointestinal motility during critical illness. Intensive Care Med 2000; 26: 901-7.
8. Lugo G, Castaneda-Hernandez G. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis. Crit Care Med 1997; 25: 806-11.
9. Barletta JF, Johnson SB, Nix DE et al. Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens. J Trauma 2000; 49: 869-72.
10. Krueger WA, Schroeder TH, Hutchison M et al. Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration. Antimicrob Agents Chemother 1998; 42: 2421-4.
11. Yagasaki K, Gando S, Matsuda N et al. Pharmacokinetics and the most suitable dosing regimen of fluconazole in critically ill patients receiving continuous hemodiafiltration. Intensive Care Med 2003; 29: 1844-8.
12. Stone JA, McCrea J, Wickersham P et al. A phase I study of caspofungin evaluating the potential for drug interactions with itraconazole, the effect of gender and the use of a loading dose regimen. In: Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 2000. Abstract 854, p. 26. American Society for Microbiology, Washington, DC, USA.
13. MSD, Sharp & Dohme Ltd. Caspofungin MSD. Summary of Product Characteristics 2004; http://www.eudra.org.
14. Stone J, Holland S, Li S et al. Effect of hepatic insufficiency on the pharmacokinetics of caspofungin. In: Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2001. Abstract A-14, p. 1. American Society for Microbiology, Washington, DC, USA.
15. Stone J, Holland S, Wickersham P et al. Drug interactions between caspofungin and tacrolimus. In: Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2001. Abstract A-13, p. 1. American Society for Microbiology, Washington, DC, USA.
16. Stone JA, Migoya EM, Hickey L et al. Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother 2004; 48: 4306-14.
17. Schwartz M, Kline W, Matuszewski B. Determination of a cyclic hexapeptide (L-743872), a novel pneumocandin antifungal agent in human plasma and urine by high-performane liquid chromatography with fluorescence detection. Anal Chim Acta 1997; 352: 299-307.
18. FDA, Guidance for Industry, Bioanalytical Method Validation, U.S. Department of Health and Human Services Food and Drug Administration, May 2001.
19. Bartizal K, Gill CJ, Abruzzo GK et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 1997; 41: 2326-32.
20. van Vianen W, de Marie S, ten Kate MT et al. Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis. J Antimicrob Chemother 2006; 57: 732-40.
21. Rajagopalan P, Pelz RK, Lipsett PA et al. Enteral fluconazole population pharmacokinetics in patients in the surgical intensive care unit. Pharmacotherapy 2003; 23: 592-602.
22. Brunner M, Pernerstorter T, Mayer BX et al. Surgery and intensive care procedures affect the target site distribution of piperacillin. Crit Care Med 2000; 28: 1754-9.
23. Tomaselli F, Dittrich P, Maier A et al. Penetration of piperacillin and tazobactam into pneumonic human lung tissue measured by in vivo microdialysis. Br J Clin Pharmacol 2003; 55: 620-4.
24. Tegeder I, Schmidtko A, Brautigam F et al. Tissue distribution of imipenem in critically ill patients. Clin Pharmacol Ther 2002; 71: 325-33.
25. Bassi C, Pederzoli P, Vesentini S et al. Behavior of antibiotics during human necrotizing pancreatitis. Antimicrob Agents Chemother 1994; 38: 830-6.
26. Mann HJ, Townsend RJ, Fuhs DW et al. Decreased hepatic clearance of clindamycin in critically ill patients with sepsis. Clin Pharm 1987; 6: 154-9.
27. Bellmann R, Egger P, Gritsch W et al. Pharmacokinetics of ciprofloxacin in patients with acute renal failure- undergoing continuous venovenous haemofiltration: Influence of concomitant liver cirrhosis. Acta Med Austriaca 2002; 29: 112-6.
28. Bauer LA, Edwards WA, Dellinger EP et al. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol 1983; 24: 643-7.
29. Mattie H. Clinical pharmacokinetics of aztreonam. An update. Clin Pharmacokinet 1994; 26: 99-106.
30. Pea F, Porreca L, Baraldo M et al. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J Antimicrob Chemother 2000; 45: 329-35.
31. Said A, Gamick JJ, Dieterle N et al. Sirolimus-itraconazole interaction in a hematopoietic stem cell transplant recipient. Pharmacotherapy 2006; 26: 289-95.
32. Vance-Bryan K, Guay DR, Gilliland SS et al. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob Agents Chemother 1993; 37: 436-40.
33. Stone JA, Holland SD, Wickersham PJ et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002; 46: 739-45.
34. Fish DN, Teitelbaum I, Abraham E. Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2005; 49: 2421-8.
35. Belzberg H, Zhu J, Cornwell EE et al. Imipenem levels are not predictable in the critically ill patient. J Trauma 2004; 56 111-7.
36. Ishihara H, Matsui A, Muraoka M et al. Detection of capillary protein leakage by indocyanine green and glucose dilutions in septic patients. Crit Care Med 2000; 28: 620-6.
37. Ishihara H, Otomo N, Suzuki A et al. Detection of capillary protein leakage by glucose and indocyanine green dilutions during the early post-burn period. Bums 1998; 24: 525-31.
38. Camacho MT, Totapally BR, Torbati D et al. Pulmonary and extrapulmonary effects of increased colloid osmotic pressure during endotoxemia in rats. Chest 2001; 120: 1655-62.
39. Stone JA, Xu X, Winchell GA et al. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 2004; 48: 815-23.
40. Yew WS, Pal SK. Correlation of microalbuminuria and outcome in patients with extensive burns. Br J Anaesth 2006; 97: 499-502.
41. Kim GH, Oh KH, Yoon JW et al. Impact of burn size and initial serum albumin level on acute renal failure occurring in major burn. Am J Nephrol 2003; 23: 55-60.
42. Birkett DJ. Pharmacokinetics Made Easy. Roseville, Australia: McGraw-Hill Compa-nies, Inc., 2002.
43. Young AB, Ott LG, Beard D et al. The acute-phase response of the brain-injured patient. J Neurosurg 1988; 69: 375-80.
44. Joukhadar C, Frossard M, Mayer BX et al. Impaired target site penetration of β-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med 2001; 29: 385-91.
45. Maschmeyer G, Glasmacher A. Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin. Mycoses 2005; 48: 227-34.
46. Arathoon EG, Gotuzzo E, Noriega LM et al. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 2002; 46: 451-7.
47. Wiederhold NP, Kontoyiannis DP, Chi J et al. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 2004; 190: 1464-71.